title: Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke.
abstract: During the past decades, candidate drugs that have shown neuroprotective efficacy in the preclinical setting have failed in clinical stroke trials. As a result, no treatment for stroke based on neuroprotection is available today. The activation of the glucagon-like peptide 1 receptor (GLP-1) for reducing stroke damage is a relatively novel concept that has shown neuroprotective effects in animal models. In addition, clinical studies are currently ongoing. Herein, we review this emerging research field and discuss the next milestones to be achieved to develop a novel antistroke therapy.
authors: Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Internal Medicine, Stockholm, Sweden.
authors: Vladimer
authors: V
authors: Darsalia
authors: Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Internal Medicine, Stockholm, Sweden.
authors: Martin
authors: M
authors: Larsson
authors: Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Internal Medicine, Stockholm, Sweden.
authors: David
authors: D
authors: Nathanson
authors: Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
authors: Thomas
authors: T
authors: Klein
authors: Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Internal Medicine, Stockholm, Sweden.
authors: Thomas
authors: T
authors: Nyström
authors: Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Internal Medicine, Stockholm, Sweden.
authors: Cesare
authors: C
authors: Patrone
mesh_terms: D000818:Animals; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism*; D004195:Disease Models, Animal; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D018027:Receptors, Glucagon / Q000819:agonists* / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology
chemical_list: C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D018696:Neuroprotective Agents; D018027:Receptors, Glucagon; D015842:Serine Proteinase Inhibitors; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4